Shoda T, Wen T, Caldwell JM, et al. - Since a necessity of more precise diagnostic tools for eosinophilic gastritis (EG) has been realized, researchers intended to construct tissue- and blood-based diagnostic platforms for EG. Across 9 Consortium of Eosinophilic Gastrointestinal Disease Researchers-associated sites, enrollment of patients with EG and non-EG controls was done. Analysis of an EG Diagnostic Panel (EGDP; gastric transcript subset) and EG blood biomarker panel (protein multiplex array) was performed. Using the expression of 18 highly dysregulated genes and dysregulated cytokines/chemokine levels, they derived EGDP₁₈ scores and Blood EG scores, respectively. In addition to detecting patients with active EG, EGDP allowed effective monitoring of disease activity in longitudinal samples and showed a high correlation in same-patient samples and an inverse correlation with gastric peak eosinophil levels, periglandular circumferential collars, and endoscopic nodularity. Significantly increased eotaxin-3, thymus and activation–regulated chemokine, IL-5, and thymic stromal lymphopoietin levels were reported for blood-based platforms. In addition to differentiating patients with EG from non-EG controls, Blood EG scores showed correlation with gastric eosinophil levels as well as an inverse correlation with EGDP₁₈ scores. For EG evaluation, tissue- and blood-based platforms were developed in this study. Robust links between particular gastric molecular profiles and histologic and endoscopic characteristics were also unveiled.